Associated Papers
Pharmacogenomics biomarkers for personalized methadone maintenance treatment: The mechanism and its potential use.
Ramli FF
Bosnian Journal of Basic Medical Sciences, 2021
Severe and prolonged cyclophosphamide-induced hepatotoxicity in a breast cancer patient carrying a CYP2B6*7 variant.
Ming Z et al.
Pharmacogenomics, 2019
Implications of genetic variation of common Drug Metabolizing Enzymes and ABC Transporters among the Pakistani Population.
Afsar NA et al.
Scientific Reports, 2019
31086207 (PubMed )
Supplement: 41598_2019_43736_MOESM1_ESM.doc
Drug-related genetic polymorphisms affecting severe chemotherapy-induced neutropenia in breast cancer patients: A hospital-based observational study.
Tsuji D et al.
Medicine, 2016
Gene polymorphisms and contents of cytochrome P450s have only limited effects on metabolic activities in human liver microsomes.
Gao N et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences, 2016
CYP2B6rs2279343 Is Associated with Improved Survival of Pediatric Rhabdomyosarcoma Treated with Cyclophosphamide.
Labib RM et al.
Plos One, 2016
Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patients.
Wang J et al.
Plos One, 2014
25372392 (PubMed )
Supplement: pone.0111694.s006.pdf
Frequencies of Cytochrome P450 2B6 and 2C8 Allelic Variants in the Mozambican Population.
Arnaldo P et al.
The Malaysian Journal of Medical Sciences : Mjms, 2013
Cytochrome P450 variations in different ethnic populations.
McGraw J et al.
Expert Opinion on Drug Metabolism & Toxicology, 2012
Interindividual variability in the prevalence of OPRM1 and CYP2B6 gene variations may identify drug-susceptible populations.
Bunten H et al.
Journal of Analytical Toxicology, 2011
Do single nucleotide polymorphisms in xenobiotic metabolizing genes determine breast cancer susceptibility and treatment outcomes?
Singh V et al.
Cancer Investigation, 2008
Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.
Nakajima M et al.
Pharmacogenetics and Genomics, 2007
Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.
Crettol S et al.
Clinical Pharmacology and Therapeutics, 2005
Select a paper to view details